Kamada Reports Q2 Earnings: EPS Beats Expectations, Revenue Misses

Kamada reported Q2 GAAP EPS of $0.13, beating the estimate by $0.04. Revenue was $44.75M, missing the estimate by $1.78M, but increasing by 5.3% YoY. The growth was primarily driven by increased sales of GLASSIA in ex-U.S. markets and higher sales of other products.

Kamada Ltd. (NASDAQ: KMDA) reported its Q2 GAAP EPS of $0.13, beating the estimate by $0.04. The company's revenue for the quarter was $44.75M, missing the estimate by $1.78M, but increasing by 5.3% year-over-year (YoY). The growth was primarily driven by increased sales of GLASSIA in ex-U.S. markets and higher sales of other products [1].

The company's adjusted EBITDA for the first half of 2025 grew 35% to $22.5 million, representing a 25% margin. Kamada has raised its 2025 adjusted EBITDA guidance to $40-44 million and maintained revenue guidance of $178-182 million [2].

Kamada continues to invest in its strategic growth pillars, including plasma collection operations and clinical trials. The company recently received U.S. FDA approval for its new plasma collection center in Houston, Texas, with an estimated annual revenue potential of $8-10 million at full capacity [3].

References:
[1] https://seekingalpha.com/news/4484502-kamada-gaap-eps-of-0_13-beats-by-0_04-revenue-of-44_75m-misses-by-1_78m
[2] https://prismmarketview.com/kamada-secures-fda-approval-for-major-houston-plasma-facility-unlocking-8-10m-annual-revenue-potential/
[3] https://www.stocktitan.net/news/KMDA/kamada-reports-strong-second-quarter-and-first-half-2025-financial-pp1969eft4k4.html